 |
32 Diseases |  |
9 Trials |
|
9 Trials |  |
795 News |  |
| «12345678910111213» |
- |||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Enrollment open, Monotherapy: ADHAND: A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy (clinicaltrials.gov) - Aug 31, 2023
P3b, N=402, Recruiting, Sponsor: LEO Pharma
Not yet recruiting --> Recruiting
- Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Continuous tralokinumab treatment over 4 years in adults with moderate-to-severe atopic dermatitis provides long-term disease control (M1+2) - Aug 30, 2023 - Abstract #EADV2023EADV_4545;
P3
Not yet recruiting --> Recruiting Continuous use of tralokinumab
- Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Safety of tralokinumab for the treatment of atopic dermatitis in patients with up to 4.5 years of treatment: an updated integrated analysis of eight clinical trials (M1+2) - Aug 30, 2023 - Abstract #EADV2023EADV_4542;
P2, P3
Continuous use of tralokinumab Long-term use of tralokinumab, for up to 4.5 years, was well tolerated, and the pattern of AEs was consistent with the initial placebo-controlled treatment period and with no new safety signals identified.
- Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Patient with follicular hyperkeratosis and hair loss. A new case of NAIAD ( NLRP1- associated autoinflammation with arthritis and dyskeratosis ) syndrome. (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_3946;
The role of the NLRP1 inflammasome appears key in keratinocyte and monocyte differentiation. Previously described cutaneous findings in this syndrome include follicular spicules, scaly plaques on trunk and extremities as well as palmar hyperkeratotic papules.
- Mnemonic aids for therapeutic monoclonal antibodies and small molecules (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_2786;
Previously described cutaneous findings in this syndrome include follicular spicules, scaly plaques on trunk and extremities as well as palmar hyperkeratotic papules. For example, the suggested mnemonic for IL-13 inhibitors,
- Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Efficacy and safety of tralokinumab for the treatment of moderate-to-severe atopic dermatitis in adult patients: a multicentre, real-life, retrospective study from AtopyReg (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_2661;
For example, the suggested mnemonic for IL-13 inhibitors, This multicentre, retrospective, real-life study seems to confirm the effectiveness of tralokinumab in AD patients on all disease aspects; the safety profile was good This data is in line with previous clinical trials.
- Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca, Ebglyss (lebrikizumab) / Roche, Almirall, Eli Lilly, Dupixent (dupilumab) / Sanofi, Regeneron
An indirect comparison of lebrikizumab, dupilumab, and tralokinumab in Japanese patients with moderate to severe atopic dermatitis by network meta-analysis methodology (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_2631;
P3
Lebrikizumab had a higher probability of yielding a higher RR and was the only medication superior to placebo on all measures. This was an indirect comparison limited by the small sample sizes in the dupilumab and tralokinumab trials.
- Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Effects of tralokinumab treatment on quantitative and qualitative measures of skin barrier function and biology in patients with moderate to severe atopic dermatitis. (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_2628;
This was an indirect comparison limited by the small sample sizes in the dupilumab and tralokinumab trials. In this small scale open clinical trial on adult patients with moderate to severe AD, tralokinumab demonstrated favorable clinical efficacy and safety, and led to significant improvements of skin barrier function parameters, improvement of microbial dysbiosis, and decreases of key SC AD biomarker expression.
- Rinvoq (upadacitinib) / AbbVie
Real-life Effectiveness and Safety of Upadacitinib in Patients with moderate to severe Atopic Dermatitis naive to any advance therapy: a multicentre, ambispective study (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_2599;
We aimed to assess the safety and effectiveness of upadacitinib in a real-world AD patient cohort that included patients who have not previously received any the advanced systemic therapies (dupilumab, tralokinumab, or another anti-JAKs inhibitors). Elevated effectiveness and favorable safety of upadacitinib were confirmed in patients previously naive to advanced systemic therapies
- Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Real-world efficacy and tolerability of tralokinumab in patients with moderate to severe atopic dermatitis (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_2594;
Taken together our data demonstrate the clinical efficacy of tralokinumab in AD patients. The clinical responsiveness was associated with an improvement of patient related outcomes and an excellent safety profile underpinning its real world efficacy and safety.
- APG777 / Apogee Therap
APG777, a humanized IgG1 mAb, binds to IL-13 with high affinity and potently blocks IL-13 signalling in multiple in vitro assays (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_2564;
APG777 demonstrated similar affinity for IL-13 as compared to lebrikizumab and tralokinumab and similar potency in multiple assays as compared to dupilumab and lebrikizumab. These data provide preclinical evidence that APG777
- Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
A global, observational, cohort study of patients with atopic dermatitis to evaluate tralokinumab real-world clinical use (TRACE): baseline characteristics from the first 100 patients in Germany (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_2561;
These data provide preclinical evidence that APG777 Initial findings showed that most adult patients with moderate-to-severe AD who were treated with tralokinumab were biologic-na
- Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
A 28-week evaluation of daily practice experience of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: results from the BioDay registry (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_2553;
Initial findings showed that most adult patients with moderate-to-severe AD who were treated with tralokinumab were biologic-na These preliminary results show that tralokinumab is effective in patients with moderate-to-severe AD, in both biological na
- Rinvoq (upadacitinib) / AbbVie
Retreatment with upadacitinib: a new therapeutic strategy in atopic dermatitis (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_2534;
JAK inhibitors are oral molecules, and therefore the probability of promoting inmune responses against the drug if suspended and reintroduced is low. Our observations need to be corroborated, but we consider that they may be relevant when managing a chronic disease that occurs in outbreakes.
- Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Survival, efficacy and safety of tralokinumab after 32 and 52 weeks of treatment for moderate-to-severe atopic dermatitis in adults: a multicentre real-world study (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_2515;
Tralokinumab maintained long-term control of AD signs and symptoms and was well-tolerated. This is a long-term prospective cohort study with limited sample size; additional real-world studies are needed to increase the reliability of our findings.
- Expert Consensus on the Systemic Treatment of Atopic Dermatitis in Special Populations (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_2495;
Herein, we provide a review and practical approach to choosing a systemic therapy that clinicians can consider when treating patients in specific clinical scenarios. Table 1.
- Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca, Ebglyss (lebrikizumab) / Roche, Almirall, Eli Lilly, Dupixent (dupilumab) / Sanofi, Regeneron
Incidence of Conjunctivitis Adverse Event in Patients Treated with Biologics for Atopic Dermatitis: A Systematic Review and Meta-analysis (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_2378;
Patients need to be counseled aboutthe incidence of conjunctivitis and its occurrence with these new agents. The high incidence of conjunctivitis with the AD indication of these medication in contrast to the other indications of these drugs raise the possibility of an association related to AD itself.
- ||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Trial completion: Efficacy and Safety of Tralokinumab Administered by an Autoinjector in Adults and Adolescents With Moderate to Severe Atopic Dermatitis (INJECZTRA) (clinicaltrials.gov) - Aug 21, 2023
P3, N=136, Completed, Sponsor: LEO Pharma
The high incidence of conjunctivitis with the AD indication of these medication in contrast to the other indications of these drugs raise the possibility of an association related to AD itself. Active, not recruiting --> Completed
- || Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Retrospective data, Review, Journal: Efficacy and safety of tralokinumab in the treatment of atopic dermatitis: A systematic review and meta-analysis of randomized controlled trials. (Pubmed Central) - Aug 10, 2023
Active, not recruiting --> Completed Tralokinumab is effective and safe in treatment of moderate-to-severe AD.
- | Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Journal: Tralokinumab Effectively Disrupts the IL-13/IL-13R?1/IL-4R? Signaling Complex but Not the IL-13/IL-13R?2 Complex. (Pubmed Central) - Aug 9, 2023
Furthermore, we demonstrate that whereas the IL-13/tralokinumab complex is unable to bind IL-13R?2, any IL-13 that is not bound by tralokinumab (i.e., free IL-13) can be bound by IL-13R?2 and subsequently internalized, regardless of the presence of tralokinumab. In summary, our study indicates that tralokinumab does not interfere with endogenous IL-13R?2-mediated regulation of free IL-13.
- Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
New Evidence Reinforcing the Value of Longterm Treatment with Tralokinumab (Industry Experts Hub 1) - Aug 3, 2023 - Abstract #EADV2023EADV_1193;
In summary, our study indicates that tralokinumab does not interfere with endogenous IL-13R?2-mediated regulation of free IL-13. Sponsored by LEO Pharma
- Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Hub 1.16 Tralokinumab (Industry Experts Hub 1) - Aug 3, 2023 - Abstract #EADV2023EADV_1192;
Sponsored by LEO Pharma Sponsored by LEO Pharma
- Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Enduring control with tralokinumab: how to visualize success (Industry Experts Hub 1) - Aug 3, 2023 - Abstract #EADV2023EADV_664;
Sponsored by LEO Pharma Sponsored by LEO Pharma
- Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Hub 1.09 Enduring control of atopic dermatitis with tralokinumab: A visual journey across the world and skin types (Industry Experts Hub 1) - Aug 3, 2023 - Abstract #EADV2023EADV_662;
Sponsored by LEO Pharma Sponsored by LEO Pharma
- Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Enduring control of atopic dermatitis with tralokinumab (Industry Experts Hub 1) - Aug 3, 2023 - Abstract #EADV2023EADV_563;
Sponsored by LEO Pharma Sponsored by LEO Pharma
- Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Tralokinumab experience from the real world (Industry Experts Hub 1) - Aug 3, 2023 - Abstract #EADV2023EADV_562;
Sponsored by LEO Pharma Sponsored by LEO Pharma
- Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Hub 1.06 Who to treat? Value of tralokinumab in atopic dermatitis from clinical practice and real-world evidence (Industry Experts Hub 1) - Aug 3, 2023 - Abstract #EADV2023EADV_561;
Sponsored by LEO Pharma Sponsored by LEO Pharma
- Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Effects of tralokinumab treatment on quantitative and qualitative measures of skin barrier function and biology in patients with moderate to severe atopic dermatitis (Hall A8) - Aug 3, 2023 - Abstract #EADV2023EADV_106;
- || Review, Journal: Effect of Biologic Therapies on Airway Hyperresponsiveness and Allergic Response: A Systematic Literature Review. (Pubmed Central) - Jul 27, 2023
No dupilumab or reslizumab studies were identified...These findings provide insights into AHR mechanisms and the precise effects of asthma biologics. Furthermore, findings suggest that tezepelumab broadly targets allergen-specific and non-allergic forms of AHR, and the underlying cells and mediators involved in asthma.
- |||||||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
New P3 trial, Monotherapy: ADHAND: A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy (clinicaltrials.gov) - Jul 25, 2023
P3b, N=402, Not yet recruiting, Sponsor: LEO Pharma
- | Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Journal, Real-world evidence, Real-world: Survival, efficacy, and safety of tralokinumab after 32 and 52?weeks of treatment for moderate-to-severe atopic dermatitis in adults: a multicentre real-world study. (Pubmed Central) - Jul 24, 2023
Furthermore, findings suggest that tezepelumab broadly targets allergen-specific and non-allergic forms of AHR, and the underlying cells and mediators involved in asthma. No abstract available
- | Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Journal: Tralokinumab shows clinical improvement in patients with prurigo nodularis-like phenotype atopic dermatitis: a multicenter, prospective, open-label case series study. (Pubmed Central) - Jul 18, 2023
No abstract available No abstract available
- | Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca, Dupixent (dupilumab) / Sanofi, Regeneron
Journal: Successfull treatment with tralokinumab in patients with atopic dermatitis and dupilumab-induced psoriasis. (Pubmed Central) - Jul 17, 2023
No abstract available No abstract available
- || Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Clinical data, Review, Journal: Tralokinumab therapy for moderate-to-severe atopic dermatitis: Clinical outcomes with targeted IL-13 inhibition. (Pubmed Central) - Jul 17, 2023
Similar results were observed in a phase 3 adolescent trial. The role of IL-13 in the pathophysiology of AD justifies a targeted approach and a wealth of clinical data supports tralokinumab as a new therapeutic option for people with moderate-to-severe AD.
- |||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
New trial: Monitoring Pregnancy and Infant Outcomes Following Tralokinumab Exposure During Pregnancy in the US and Canada - PROTECT (clinicaltrials.gov) - Jul 10, 2023
P=N/A, N=900, Recruiting, Sponsor: University of California, San Diego
- Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Tralokinumab in the treatment of resistant atopic dermatitis: an open-label, retrospective case series study () - Jul 3, 2023 - Abstract #WCD2023WCD_5007;
Tralokinumab can be effective and safe in short-term improvement of symptoms in AD patients unresponsive to other systemic treatments, including dupilumab. A clinical response was obtained in patients presenting AD phenotypes particularly resistant to other conventional treatments, such as hand eczema, PN-like lesions, and portrait dermatitis
- Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Quality of life in atopic dermatitis and tralokinumab: a real life experience () - Jul 3, 2023 - Abstract #WCD2023WCD_4988;
Data highlight the drastic improvement of the quality of life of our patients during treatment, starting as early as the first month, and continuing over the long term . As our patients said
- Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca, Dupixent (dupilumab) / Sanofi, Regeneron, Rinvoq (upadacitinib) / AbbVie
Efficacy of tralokinumab after failure with upadacitinib and dupilumab in a patient affected by atopic dermatitis () - Jul 3, 2023 - Abstract #WCD2023WCD_4935;
KEY MESSAGES: Despite the significant increase in possible systemic therapies for AD, a "multi-failure" patient population is emerging. Treatment of this population is still an unmet need
- Comparison of patient's profile initiating anticytokines and JAK inhibitors for atopic dermatitis in the OMCCI cohort () - Jul 3, 2023 - Abstract #WCD2023WCD_4905;
JAKi were initiated in younger patients This can be explained by the safety profile of JAKi. Revision process of JAKi
- Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca, Dupixent (dupilumab) / Sanofi, Regeneron
Comparison of different skin care regimens for patients with moderate to severe atopic dermatitis in addition to systemic treatment: results of a multicenter randomized controlled trial () - Jul 3, 2023 - Abstract #WCD2023WCD_4904;
In patients with moderate to severe AD receiving systemic treatment, additional treatment with Emollient+ significantly improves pruritus and quality of life aspects compared to routine treatment with commercial emollients. In addition, patients under Emollient+ regimen used less emollient balm compared to control group
- Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
First audit of tralokinumab treatment in real-world biologic-experienced cohort in the UK () - Jul 3, 2023 - Abstract #WCD2023WCD_3857;
Limitations include the small n number, hard-to-treat nature of the EUS cohort, and heterogeneity of clinical outcome reporting. Further work to determine real world experience in biologic-na
- | Adbry (tralokinumab) / LEO Pharma, AstraZeneca
Journal: Tralokinumab in elderly atopic dermatitis. (Pubmed Central) - Jun 30, 2023
Further work to determine real world experience in biologic-na No abstract available
- |||| Adbry (tralokinumab) / LEO Pharma, AstraZeneca, lebrikizumab (LY3650150) / Roche, Almirall, Eli Lilly, Dupixent (dupilumab) / Sanofi, Regeneron
Clinical: Apogee engineers drugs w/ longer half-lives. In #atopicdermatitis, blockbuster @Sanofi & @RegeneronPharma med #Dupixent, @LEOHealthySkin's #Adbry & @EliLillyandCo's experimental #lebrikizumab are dosed every 2-4 weeks. $APGE's goal is 2-3 month maintenance dosing. $SNY $REGN $LLY (Twitter) - Jun 26, 2023
- || Review, Journal: Updated Review on Treatment of Atopic Dermatitis. (Pubmed Central) - Jun 19, 2023
We begin with topical treatments such as corticosteroids and calcineurin inhibitors and subsequently address the latest systemic treatments, such as Janus kinase inhibitors (upadacitinib, baricitinib, abrocitinib, gusacitinib) and interleukin (IL) inhibitors, which have proven efficacious in AD, namely, dupilumab (IL-4 and IL-13), tralokinumab (IL-13), lebrikizumab (IL-13), and nemolizumab (IL-31). Given the large number of drugs available, we summarize the pivotal clinical trials for each drug, evaluate recent real-world experience in terms of safety and efficacy for purposes of compilation, and provide evidence to guide the optimal choice of therapy.
- Adbry (tralokinumab) / LEO Pharma, AstraZeneca
A global, observational, cohort study of patients with atopic dermatitis to evaluate tralokinumab real-world clinical use (TRACE): baseline characteristics from the first 100 patients in Germany () - Jun 19, 2023 - Abstract #RAD2023RAD_101;
Given the large number of drugs available, we summarize the pivotal clinical trials for each drug, evaluate recent real-world experience in terms of safety and efficacy for purposes of compilation, and provide evidence to guide the optimal choice of therapy. Initial findings from the first 100 patients from TRACE in Germany showed that the majority of adult patients with moderate-to-severe AD treated with tralokinumab were biologic-na
- Comparative efficacy of targeted systemic therapies for moderate-to-severe atopic dermatitis without topical corticosteroids: an updated network meta-analysis () - Jun 19, 2023 - Abstract #RAD2023RAD_86;
P3
Initial findings from the first 100 patients from TRACE in Germany showed that the majority of adult patients with moderate-to-severe AD treated with tralokinumab were biologic-na Among targeted treatments for moderate-to-severe AD used without concomitant topical corticosteroids for 12 to 16 weeks, upadacitinib 30 mg remains the most efficacious therapy in this NMA, generally followed by abrocitinib 200 mg, upadacitinib 15 mg, dupilumab 300 mg, and lebrikizumab 250 mg or abrocitinib 100 mg.
- A CME virtual patient simulation activity evaluated the management of adults with atopic dermatitis () - Jun 19, 2023 - Abstract #RAD2023RAD_83;
- Adbry (tralokinumab) / LEO Pharma, AstraZeneca
Early insights into the characteristics of tralokinumab patients in a real-world setting in the United States () - Jun 19, 2023 - Abstract #RAD2023RAD_76;
This study provides early insights into the characteristics of tralokinumab patients in a real-world setting. While many characteristics were similar between biologic-na
- || Adbry (tralokinumab) / LEO Pharma, AstraZeneca, lebrikizumab (LY3650150) / Roche, Almirall, Eli Lilly
Review, Journal: Investigational anti IL-13 asthma treatments: a 2023 update. (Pubmed Central) - Jun 14, 2023
Other attempts to block or, at least limit, the impact of IL-13 in asthma, such as the use of protein-protein interaction modulators, kinase inhibitors, bispecific antibodies, or IL-13 peptide vaccines, are largely still in the preclinical stage of development, and it is difficult to predict whether they will reach clinical development. Nevertheless, since IL-13 directly affects airway contractility and is critical for mucus production and remodelling, and airflow limitation and mucus hypersecretion are commonly treatable features in asthma, we suggest including an anti-IL-13 drug before GINA step 5.
- | lebrikizumab (LY3650150) / Roche, Almirall, Eli Lilly
Journal: Binding, Neutralization and Internalization of the Interleukin-13 Antibody, Lebrikizumab. (Pubmed Central) - Jun 13, 2023
Additionally, lebrikizumab does not interfere with IL-13 clearance. Lebrikizumab has a different mode of action to both tralokinumab and cendakimab, possibly contributing to the clinical efficacy observed by lebrikizumab in Ph2b/3 AD studies.